Cochrane · systematic review · CD012836
Linezolid for drug‐resistant pulmonary tuberculosis
Singh, B, Cocker, D, Ryan, H, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
8
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 1 · 10%Very low 8 · 80%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Linezolid compared to no linezolid for drug‐resistant pulmonary tuberculosis
Population: drug‐resistant pulmonary tuberculosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death Linezolid vs no linezolid | RR 0.65 [0.12, 3.62] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment failure Linezolid vs no linezolid | RR 0.26 [0.1, 0.7] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Cure Linezolid vs no linezolid | RR 2.36 [1.13, 4.9] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment interrupted Linezolid vs no linezolid | RR 1.29 [0.31, 5.33] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment completed Linezolid vs no linezolid | RR 1.45 [0.45, 4.68] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Sputum culture conversion at 24 months Linezolid vs no linezolid | RR 2.1 [1.3, 3.4] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Total adverse eventsg Linezolid vs no linezolid | no estimate extracted | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events Linezolid vs no linezolid | no estimate extracted | NR | No studies |
Antituberculous treatment discontinuationj Linezolid vs no linezolid | RR 1.94 [0.18, 20.35] | 1 study · 65 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Linezolid discontinuationl Linezolid vs no linezolid | no estimate extracted | 1 study · 65 participants | Ungraded |